WhatsApp-based Psycho-socio-educational Intervention (WeLove) for Prevention of Psychological and Sleep Problems in Pregnant Women and Their Partners: A Three-arm Double-blinded Pilot Randomised Controlled Trial
Launched by CHINESE UNIVERSITY OF HONG KONG · Jan 6, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called WeLove, is exploring how a program delivered through WhatsApp can help pregnant women and their partners with psychological and sleep problems. The main goals are to see if this online support is helpful and acceptable, as well as to understand how psychological issues, like anxiety and stress, relate to sleep quality during pregnancy. The study will involve 60 couples who will be randomly placed into one of three groups: one group will receive the full WeLove intervention, another group will only include the pregnant women, and the last group will use WhatsApp as usual without any special support.
To be eligible for the study, participants need to be pregnant (between 12 and 28 weeks) and their partners must be over 18. They should be able to read and understand Chinese and have access to a device that can use WhatsApp. The trial is currently recruiting participants, and those who join can expect to participate in six online sessions that focus on psychological, social, and educational support. After the program, researchers will follow up with interviews to gather feedback on the experience. This study aims to help improve the well-being of expecting parents during this important time.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • pregnant with a gestation of \>12 to 28 weeks and their partners over 18 years
- • able to read and understand Chinese
- • have electronic devices with WhatsApp that can contact the Internet
- • can provide written consent and voluntary participation in this study
- Exclusion Criteria:
- • current severe medical illnesses
- • psychological and sleep disorders
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported